CS Paper Radar

Binding Mode Matters: Hotspot-Aware Drug Discovery via Explorative Preferences

Dingshuo Chen, Hao Yang, Kuangqi Zhou, Zhixun Li, Qiang Liu, Xiangxiang Zeng, Shu Wu, Yaosen Min

cs.LG cs.AI ·submitted 2026-11-11 03:03 UTC · v1
top venue

Abstract

Discovering hit molecules requires not just high binding affinity, but also the identification of diverse binding modes, which are critical for experimental assays. Existing generative approaches have predominantly relied on optimizing a scalar docking score, obscuring the distinct contributions of key binding determinants. To this end, we introduce a paradigm shift by formulating target-based drug design as a multi-objective exploration task, where each objective explicitly corresponds to enhancing interactions with a specific hotspot. Here, we introduce BindMol, a novel generative framework driven by a customized multi-objective reinforcement learning algorithm. By incorporating explorative preferences during training, our approach efficiently uncovers molecules with diverse and desirable binding profiles. Empirical results demonstrate that BindMol facilitates the discovery of high-affinity compounds characterized by both structural novelty and diverse binding modes. Validated across target-based drug discovery and multi-property optimization tasks, our approach provides a versatile paradigm for goal-oriented drug discovery.

Comment
To appear at NeurIPS 2026, 26 pages

Closest papers

Nearest neighbours by meaning across the whole index.

ProbeMatchDTI: Probe-Driven Multi-Scale Biochemical Pattern Matching for Drug-Target Interaction Prediction

cs.LG cs.AI ·2026-09-02 ·Quan Hao, Mengyue Fan, Zifan Dong, Youru Li, Jianduo Zhao +6 more
code/data similarity 0.72
Abstract

Drug-target interaction (DTI) prediction is an important task in AI-driven drug discovery. Although recent biochemical representation learning methods have improved DTI prediction, their passive feature aggregation tends to favor dominant molecular patterns while suppressing weak yet binding-relevant signals, such as functional groups and residue-context patterns, limiting the modeling of multi-scale biochemical correspondences. To address this issue, we propose ProbeMatchDTI, a pattern-probe-driven framework comprising IterProbe and BindingProbe. IterProbe explicitly retains contextual states across refinement depths and uses learnable probes to select them at each position before cross-entity matching, thereby preserving weak biochemical patterns and strengthening associations among functional groups, local motifs, and molecular scaffolds. BindingProbe then characterizes cross-entity drug-protein complementarity at local biochemical-unit and whole-pair levels, jointly modeling fine-grained interactions and multi-scale correspondences while preserving weaker binding-relevant associations. Extensive experiments demonstrate the superiority of ProbeMatchDTI, achieving 2.0% and 0.5% higher AUC-ROC on BindingDB and DrugBank, respectively. Feature-level pattern analyses further characterize its probe-driven behavior in cross-scale biochemical pattern matching. We further connect ProbeMatchDTI predictions with an evidence-guided downstream drug-discovery workflow, demonstrating their utility for candidate refinement and validation planning. Our code is available at https://github.com/developer-hq/ProbeMatchDTI

0.47

On the Selectivity of Generative Models in Structure-Based Drug Design

cs.LG cs.AI ·2026-10-16 ·Ella Miray Rajaonson, Jungyoon Lee, William Chau, Alan Aspuru-Guzik, Benjamin Sanchez-Lengeling +3 more
top venuebenchmarkcode/data similarity 0.72
Abstract · Accepted as a Presentation at the Neural Information Processing Systems 2026

Designing small-molecule drugs that selectively bind to a target protein while avoiding unintended interactions with other proteins is essential for reducing side effects that contribute substantially to clinical attrition. Although structure-based drug design (SBDD) has advanced rapidly with deep learning, most generative models still optimize binding to a single target and disregard selectivity due to limited training data and unknown off-target interactions. Motivated by this gap, we introduce SELECTBENCH, a comprehensive benchmark assessing the selectivity of generative SBDD models. SELECTBENCH provides three curated evaluation tasks reflecting different real-world drug discovery scenarios: literature-based case studies, safety screening panels used in pharmaceutical development, and large-scale structure-based evaluation sets. We further introduce a suite of metrics to quantify selectivity and conduct a systematic evaluation of nine representative SBDD models, including methods explicitly trained for selectivity and widely-used inference-time guidance techniques. Our results show that even selectivity-trained models achieve only modest off-target discrimination and inference-time guidance provides limited gains, underscoring the need for method improvement. SELECTBENCH provides both a characterization of where current generative SBDD stands on selectivity and an open, extensible platform to accelerate progress. The benchmark is available at https://github.com/lovetaro/selectbench.

0.44

PMO-Dock: Benchmarking Docking, Specificity, and Generalization in Molecular Optimization

cs.LG q-bio.QM ·2026-10-13 ·Gor Simonyan, Tatevik Abrahamyan, Narek Abelyan, Tigran Fahradyan, Hrant Khachatrian
benchmark similarity 0.71
Abstract

The Practical Molecular Optimization (PMO) benchmark standardized evaluation in molecular optimization, but it is built on simple property-based oracles that do not capture structure-based drug design. As the field has moved to docking-based objectives, evaluation practice has become unstandardized, and different methods report results on different docking tasks, often without a shared protocol for fair comparison or sample-efficiency constraints. To address this, we introduce Practical Molecular Optimization for Docking (PMO-Dock), a benchmark and protocol for docking-based optimization consisting of 25 tasks covering hit generation, lead optimization, and a new specificity task requiring strong on-target binding while penalizing off-target interactions. The protocol separates model development from final evaluation: validation tasks are used for hyperparameter tuning, and test tasks are held out for final evaluation and are not used during development. Evaluation on the test tasks is done under a strict oracle budget to reflect realistic drug-discovery settings. We benchmark four diverse high-performing methods spanning different optimization paradigms, Saturn (reinforcement learning), GenMol (discrete diffusion), Genetic-guided GFlowNet, and ChemLlama (LLM-based evolutionary search). Our results show no universally best method across tasks, additional analyses of hyperparameter transfer (cross-task and cross-category) and sensitivity show that transfer is often limited and varies by method, motivating method-dependent selection strategies. This benchmark provides a concrete standard for evaluating generalization to unseen tasks and sample efficiency under a limited test-time oracle budget.

0.18

PairIT: Autoregressive Transformers for Low-Data Molecule Optimization

cs.LG cs.AIphysics.chem-ph ·2026-10-13 ·Hannah Lawrence, Bodhi P. Vani, Ji Won Park, Natasa Tagasovska, Samuel Don Stanton +3 more
similarity 0.71
Abstract

Generating novel molecules with desired properties is a central challenge in drug discovery. Although foundational work focused on de novo generation, practical use cases require a more complex setting: conditioning on an initial seed molecule, optimizing multiple properties, and operating in data-sparse regimes. We introduce PairIT, a flexible training framework for autoregressive transformers over SMILES sequences that enables seeded generation by learning from pairs of structurally similar molecules. By leveraging matched pairs, the model learns to generate local, chemically meaningful edits that improve a property of the seed molecule. Prompt tokens extend this framework by specifying the target property, desired direction, and approximate magnitude of change. Multiple prompt tokens can be concatenated to enable multi-property optimization at inference time. For properties where pair supervision alone is insufficient, reinforcement learning post-training can further improve optimization, providing a tunable trade-off between proximity to the seed and the optimization objective. PairIT naturally supports pretraining on a large dataset and fine-tuning on a smaller dataset, which is critical for performance in data-sparse regimes. Surprisingly, we observe diminishing returns to the scale of the pretraining dataset. We demonstrate empirically on MoleculeNet and Therapeutics Data Commons datasets that, with appropriate paired-data curation, a standard transformer model of modest size (68M parameters) can achieve robust seeded molecular optimization in low-data regimes.

0.21

SpecOpt: Contact-Diff Reasoning for Agentic Molecule Optimization Toward Binding Specificity

cs.AI ·2026-09-18 ·Thao Nguyen, Heng Ji
benchmark similarity 0.70
Abstract

Off-target protein binding is a major source of adverse effects for small-molecule drugs, yet most structure-based molecular design methods focus on generating selective compounds de novo rather than improving the selectivity of existing, well- characterized drugs. We introduce specificity optimization (SpecOpt), a molecular design task that seeks constrained structural modifications to an existing compound that increase its binding preference for an intended target over known off-targets while preserving its structural identity and drug-like properties. To enable systematic evaluation, we construct a ChEMBL-derived benchmark from compound-target interaction data, identifying intended targets through curated drug-mechanism annotations and off- targets through measured activities. We then develop an agentic framework that docks each compound against its intended target and off-targets, compares the resulting poses through residue-aware atom-protein contacts, and provides these differential interactions to a large language model to propose targeted structural modifications. Candidates are retained only if they satisfy molecular similarity, ADMET, and target-off-target docking selectivity criteria. On 915 compounds, the agent improves the target- off-target binding gap for 84.8% of compounds, shifting the mean gap from -0.72 to +0.47 kcal/mol while maintaining a mean Tanimoto similarity of 0.72 to the starting compounds. Ablation studies identify residue-specific contact information as the critical optimization signal: replacing residue identities with binary contact indicators eliminates improvement on all 29 ablation compounds. These results establish SpecOpt as a distinct molecular design problem and demonstrate residue-aware differential interactions as an effective signal for improving the specificity of existing compounds.

0.08

MFG: Multi-turn Feedback Guided Molecular Optimization

cs.AI cs.LGq-bio.QM ·2026-10-13 ·Trieu Nguyen, Frazier N. Baker, Ruoxi Gao, Daniel Adu-Ampratwum, Xia Ning
similarity 0.69
Abstract

Multi-objective molecular optimization is a critical process in drug discovery that aims to modify a given molecule to simultaneously improve multiple properties while maintaining a similar overall structure. This process often requires iterative modifications guided by computational or experimental feedback. Recent large language model (LLM)-based methods have begun to explore this iterative approach; however, these methods are not explicitly trained to leverage such feedback, while existing approaches primarily focus on single-turn molecular optimization. To address this gap, we introduce Multi-turn Feedback Guided (MFG) molecular optimization, a reinforcement learning framework that trains an LLM to progressively optimize molecules using feedback from previous turns. MFG introduces a feedback vector capturing both property improvements and source molecule similarity, alongside a feedback-aligned reward function that promotes progressive improvement across turns. We apply MFG over $\text{GeLLM}^{3}\text{O}$, a state-of-the-art LLM model for multi-objective molecular optimization, evaluate $\text{GeLLM}^{3}\text{O-MFG}$ on ten multi-objective molecular optimization tasks. The results demonstrate that $\text{GeLLM}^{3}\text{O-MFG}$ achieves the highest average similarity-constrained success rate ($81.50%$), outperforming the base model $\text{GeLLM}^{3}\text{O}$ ($70.81%$).

0.17

MolHop: Scaffold-Hopping Molecular Design with Agentic Reinforcement Learning

cs.LG cs.CL ·2026-10-14 ·Yanyi Su, Chenyan Wang, Yulei Gong, Yeyun Chen, Xiaohui Yang +1 more
similarity 0.68
Abstract · Under review at ICLR 2027

Molecular design is often formulated as an optimization problem over existing molecular spaces. However, molecular optimization and the discovery of structurally distinct replacement molecules represent two fundamentally different search problems. LLM-based molecular design agents typically perform the former, conducting local refinement within the neighborhood of existing structures to improve target properties through structural modifications. In contrast, the latter requires exploration of a broader chemical space to discover molecules with entirely different scaffolds while preserving the functional characteristics of reference molecules. We propose MolHop, an agentic framework for cross-scaffold molecular discovery that enables models to navigate and edit within a pre-organized chemical space. MolHop organizes approximately 1.6 million molecular scaffolds from commercial molecules into a coarse-to-fine hierarchical action space. The agent selects new exploration regions through scaffold navigation actions and adjusts candidate properties through molecular editing. The framework maintains historical trajectory memory to support long-horizon search processes. On drug molecule and commercial compound tasks, connecting Grok-4.6 and DeepSeek-Flash-V4.1 to the MolHop framework substantially improves their cross-scaffold joint success rates. We develop MolHop-9B through agentic reinforcement learning, and MolHop-9B outperforms generative baselines including GPT-5.6-sol, Claude-5-Opus, and Gemini-3.1-Pro, while generating candidate molecules with larger scaffold differences from the reference molecules. These results demonstrate that effective molecular discovery beyond the traditional optimization paradigm requires structured chemical and action spaces, enabling agents to explore new structural regions rather than merely refine existing molecules.

0.19

Multi-Objective Protein Optimization via Modular Diffusion Steering

cs.LG ·2026-10-20 ·Meir Roketlishvili, Felix Huber, Wenda Chu, Yisong Yue, Raul Astudillo
similarity 0.68
Abstract

Protein engineering often requires improving several properties simultaneously, motivating the search for high-performing sequences that represent useful fitness tradeoffs. Discovering these sequences is challenging because the design space is combinatorially large and experimental campaigns often permit only a few rounds of batched measurements. We introduce \textit{MODS}, a modular framework for multi-objective protein optimization via inference-time diffusion steering. For each proposal, MODS samples augmented Chebyshev scalarization weights and a fitness-surrogate ensemble member to define a scalar steering reward. Varying the weights directs generation toward different objective tradeoffs, while varying ensemble members diversifies the predictions used for guidance. Because MODS expresses multi-objective acquisition through scalar rewards, it can be paired with different diffusion models and compatible steering procedures. After each evaluation batch, MODS updates the surrogates without retraining the generative model. We evaluate MODS on six protein optimization tasks using predictive oracles trained on experimental assay data, with two diffusion models and two steering procedures. MODS achieves competitive final hypervolume across all six tasks with both diffusion models, and substantially outperforms the best evaluated baseline on several tasks. Our results demonstrate a flexible and effective approach to multi-objective protein optimization with limited feedback.

0.08